Sandhoff disease is a GM2 gangliosidosis caused by mutations in HEXB encoding the b-subunit of b-hexosaminidase A. b-Hexosaminidase A exists as a heterodimer consisting of a-and b-subunits, and requires a GM2 activator protein to hydrolyze GM2. To investigate the molecular pathology in an adult Sandhoff disease patient with an early disease onset, we performed mutation detection, western blot analysis and molecular simulation analysis. The patient had compound heterozygous mutations p.Arg505Gln and p.Ser341ValfsX30. Western blot analysis showed that the amount of mature form of the a-and b-subunits was markedly decreased in the patient. We then performed docking simulation analysis of the a-and b-subunits with p.Arg505Gln, the GM2AP/GM2 complex and b-hexosaminidase A, and GM2 and b-hexosaminidase A. Simulation analysis showed that p.Arg505Gln impaired each step of molecular conformation of the a-and b-subunits heterodimer, the activator protein and GM2. The results indicated that p.Ser341ValfsX30 reduced the amount of b-subunit, and that p.Arg505Gln hampered the maturation of a-and b-subunits, and hindered the catalytic ability of b-hexosaminidase A. In conclusion, various methods including simulation analysis were useful to understand the molecular pathology in Sandhoff disease.
INTRODUCTION
Sandhoff disease (SD) is an autosomal recessive disorder resulting in accumulation of the ganglioside GM2 in the nervous system because of mutations in HEXB. 1 The prevalence of Sandhoff disease in nonJewish populations is 1 in B310 000 live births. Sandhoff carrier frequency in non-Jewish populations is 1 in B278. 1 More than 20 different mutations in HEXB are reported. 2 SD is classified into three phenotypes: infantile SD; juvenile SD; and adult SD. 2 Infantile SD and juvenile SD usually follow an acute or subacute clinical course, and patients die 3-10 years after disease onset. Young patients demonstrate widespread symptoms related to the nervous system, including motor weakness, hypotonia, mental retardation, dysarthria, visual disturbance, seizure, ataxia, diarrhea and constipation. 2, 3 In contrast, adult SD patients display a chronic disease course with the nervous system affected by spinocerebellar degeneration, [4] [5] [6] [7] motor neuron disease, [7] [8] [9] [10] and sensory or autonomic dominant peripheral neuropathy. 11 SD results from mutations in HEXB encoding the b-subunit that is shared between b-hexosaminidase (b-Hex) A and b-Hex B. b-Hex A exists as a heterodimer consisting of a-and b-subunits (ab-heterodimer), whereas b-Hex B exists as a homodimer consisting of the b-subunit (bb-homodimer). 2 Enzymatic analysis with 4-methylumbelliferyl (4-MU) substrates showed reduced catalytic abilities of b-Hex A and b-Hex B in SD. 2, 12, 13 The decreased catalytic abilities of the enzymes with 4-MU substrates can be explained by the presence of the mutant b-subunit shared between b-Hex A and b-Hex B. 13 Hydrolysis of 4-MU substrates does not require the presence of the GM2 activator protein (GM2AP), but the presence of GM2AP is essential for hydrolysis of GM2 in humans. 2, 14 Enzymatic analysis with 4-MU substrates cannot therefore fully reflect the in vivo functions of b-Hex A and b-Hex B.
Reduced activity of mutant b-Hex A may be the primary cause of accumulation of GM2 in SD, as GM2AP specifically binds to b-Hex A. 2, 14 However, it is not clear if mutant b-Hex B contributes to the development of SD. Therefore, study of the pathogenesis of SD first requires examination of ab-heterodimer formation and the catalytic activity of b-Hex A. The formation of the ab-heterodimer in b-Hex A is critical not only for acquisition of catalytic ability but also for enzyme transport to lysosomes. 15, 16 Impairment of enzyme transport may also affect the residual activities of b-Hex A. Formation of the ab-heterodimer in b-Hex A is therefore important in GM2 metabolism because it may determine (1) the catalytic ability and lysosomal transport of b-Hex; (2) the residual activity of b-Hex A; and (3) the clinical phenotype of SD.
In this study, to clarify the molecular pathology of SD in an adult patient with a relatively early disease onset, we searched for HEXB mutations and performed molecular simulation analysis with the mutant b-subunit. Using molecular simulation, we analyzed the conformational stability of b-Hex A, binding of the GM2AP/GM2 complex to b-Hex A and GM2 hydrolysis. Insights into the molecular pathology of SD may lead to the development of novel treatments for lysosomal disorders.
PATIENT AND METHODS Patient
The patient was a Japanese female born to healthy and non-consanguineous parents. At age 6, she had difficulty in running; at age 13, she could no longer run. Gait disturbance appeared and gradually worsened during high school. A neurological examination at age 20 revealed a prominent gait disturbance, ataxia in the limbs and trunk, and proximal muscle weakness and atrophy predominantly affecting the lower limbs. A cherry-red spot was absent in the macula of both eyes. Patellar tendon reflexes were weak. Pathological reflexes were absent. The intelligence quotient score was 71 on the Wechsler Adult Intelligence Scale-Revised. Brain magnetic resonance imaging revealed marked cerebellar atrophy, but T 2 -weighted images showed no abnormal intensity in the basal ganglia, thalamus and cerebral white matter (Figure 1 ). Nerve conduction studies were normal. Needle electromyography revealed chronic neurogenic patterns in the proximal muscles of the lower limbs.
The patient and her parents gave their informed consent for the enzyme activity assay and genetic analysis.
Sample preparation
Peripheral leukocytes were extracted using the following methods. Blood was collected using EDTA-coated tubes. To lyse erythrocytes, 28 ml of ammonium chloride solution (0.155 mM NH 4 Cl, 10.0 mM KHCO 3 , 0.100 mM EDTA2Na) was added to 7 ml of blood and mixed. The mixture was centrifuged at 4 1C for 10 min at 1500 r.p.m., and the supernatant was removed. To wash the sediment, the following procedure was repeated twice: 15 ml of normal saline solution was added to the mixture. The mixture was centrifuged at 4 1C for 10 min at 1500 r.p.m., and the supernatant was removed.
Genomic DNA was extracted from peripheral blood using a DNA extraction kit (SepaGene; Sanko Junyaku, Tokyo, Japan), according to the manufacturer's instructions.
Total protein was purified from peripheral leukocytes using Qiagen kits (QIAshredder, AllPrep kit; Qiagen, Venlo, The Netherlands), according to the manufacturer's instructions.
Enzyme activity assay
Enzyme activity was measured in the laboratory of SRL Inc (Tokyo, Japan) using the following methods. Peripheral leukocytes were prepared (as above). Leukocyte cell membranes were disrupted by sonication, and the supernatant after centrifugation was used for enzyme activity assay. To study b-Hex A activity, an aqueous reaction mixture (100 ml) containing 50 ml of cell extract, 6 mM 4-methylumbelliferyl-N-acetyl-b-D-glucosaminide-6-sulfate (4-MUGS), 13 0.1 M citrate and 0.2 M phosphate buffer (pH 4.0) was used. The reaction proceeded with incubation at 37 1C and was stopped after 60 min by adding 1500 ml of 0.2M glycine buffer (pH 10.7). To study total b-Hex activity, a reaction mixture (100 ml) containing 50.0 ml of cell extract, 2 mM of 4-methylumbelliferyl-N-acetyl-b-D-glucosaminide (4-MUG) 13 and 0.1 M citrate buffer (pH 4.5) was used. The reaction proceeded with incubation at 37 1C and was stopped after 30 min by adding 1500 ml of 0.2 M glycine buffer (pH 10.7). The activity of each enzyme was determined as the amount of the fluorescent molecule (4-MU) that emits light at 450 nm when excited by 365 nm light. Enzyme activity was adjusted according to the protein concentrations as measured using the Lowry method. 17 Control studies of enzyme activity were performed using the enzyme obtained from healthy volunteers (b-Hex A: n ¼ 48; total b-Hex: n ¼ 100) at SRL Inc.
Genetic analysis of HEXB
Polymerase chain reaction (PCR) amplification of each exon of HEXB in genomic DNA was performed using a PC-701 thermal cycler (Astec, Tokyo, Japan), according to the method of Narkis et al. 18 The PCR fragment was then sequenced directly: the fragment underwent a cycle sequencing reaction using a BigDye Terminator v3.0 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA), was applied to the genetic analyzer ABI PRISM 310 (Applied Biosystems) and was analyzed using DNA sequencing analysis software (Applied Biosystems).
Western blot analysis
The amounts of a-and b-subunits in peripheral leukocytes were determined by western blot analysis using rabbit anti-a-and -b-subunit antibodies (product code: ab91624 and ab140649, abcam, Cambridge, UK). The precursors of a-and b-subunits undergo post-translational proteolytic and glycosidic processing in the endoplasmic reticulum, Golgi and lysosomes to produce the mature form. 2, 19 Both antibodies also recognize these precursors of the subunits as well as the mature form. Mouse anti-tubulin antibodies were used as the basis for correction. Proteins were extracted as above and then subjected to sodium dodecylsulfate-polyacrylamide gel electrophoresis using a Mini-PROTEAN system and 4-20% precast polyacrylamide gel (Bio-Rad, Hercules, CA, USA). Proteins were then transferred to 0.45 mm of nitrocellulose membrane using a Criterion Blotter (Bio-Rad), and visualized by immunostaining using the same antibodies as above and an ImageQuant LAS 4000 system (GE Healthcare UK Ltd., Buckinghamshire, UK).
Simulation analysis
Construction of the three-dimensional structure of b-Hex A. The known crystal structure of b-Hex A was the only mature form 20 ( Figure 2 ). Therefore, in this paper, based on the data of Lemieux et al., 20 we performed simulation analysis of the mature forms of the a-subunit, b-subunit and b-Hex A at those locations in lysosomes. 2, 20 The crystal structure of the b-Hex A octamer was Computing Group Inc., Montreal, Quebec, Canada), which was used for homology modeling in a previous report. 22 The 3-D structure of mutant b-Hex A was constructed by introducing the p.Arg505Gln mutation into the b-subunit and then performing energy minimization. Protein structures were protonated at pH 5.0, that is, the same pH as that within lysosomes. The ionized residues in b-Hex A at pH 5.0 are listed in the Supplementary Information. The structures were soaked into water molecules and subjected to molecular mechanics calculations using the AMBER99 force field until the root mean square (RMS) gradient was less than 0.01 kcal mol À1 Å À1 . Following this, 100-ps molecular dynamics simulations were performed with a time step of 1.5 fs at 300 K using the NVT (constant composition, volume and temperature) ensemble. The 3-D structure of b-Hex A obtained in this process was superimposed onto the structure of the ab-heterodimer in PDB;2GJX (chain A and B). Then the root mean square deviation (RMSD) value of 1.01 Å was calculated for all Ca atoms.
Docking simulation of a-and b-subunits, and conformational stability of b-Hex A. Docking simulation of the a-and b-subunits of b-Hex A was carried out to analyze the conformational stability of b-Hex A. In this analysis, we used ZDOCK software, as used by Wang et al., 23 to evaluate the binding between molecules. Two thousand dockings of the a-and b-subunits were performed using ZDOCK with default parameters, and ZDOCK scores were analyzed. 24 The docking site of each dimer was defined according to the crystal structure of b-Hex A, as described by Leimeux et al. 20 Construction of the 3-D structure of GM2AP/GM2 complex. The 3-D structure of the activator protein GM2AP was downloaded from the Protein Data Bank (PDBID: 1PU5). The 3-D structures of nine GM2 molecules were obtained from ChemSpider (ID: 1674492-5, 16744927-32). In this part of the analysis, we used MOE software with reference to past reports evaluating the substrate binding sites of enzymes. 25 MOE software was used for a total of 2000 docking runs of GM2AP and GM2, using the docking site described by Wright et al. 26 The GM2AP/GM2 complex structures closest to the one described by Wright et al. 26 were selected, and subjected to energy minimization to allow construction of the 3-D structure of the complex of GM2AP/GM2 and b-Hex A.
Docking simulation of GM2AP/GM2 complex and b-Hex A. Five thousand docking runs of each of the nine GM2AP/GM2 complexes and b-Hex A were carried out six times using ZDOCK (total 45 000 Â six runs). Docking sites of the GM2AP-GM2 complex and b-Hex A were defined according to a predicted model of the human Hex A-GM2-activator quaternary complex as reported by Mark et al. 19 Construction of the model structure of b-Hex A via GM2AP/GM2 complex. The 3-D GM2AP/GM2/b-Hex A complex structures closest to the one predicted by Mark et al. 19 were selected and subjected to energy minimization. GM2AP and GM2 were then removed from each complex. Energy minimization was performed before each removal step. The resultant structure of b-Hex A was used for the following simulation analysis.
Prediction of GM2 hydrolysis ability of b-Hex A. The GM2 hydrolysis ability of b-Hex A was predicted by means of docking simulations of GM2 and b-Hex A, constructed as above. The docking site was defined at around Asp322 and Glu323 in the a-subunit of b-Hex A, which, according to Lemieux et al. 20 and Mark et al., 19 is involved in ligand binding and/or protonation of the departing carbohydrate. For each of the nine b-Hex A, 5000 docking runs with GM2, which were used for construction of each b-Hex A, were performed using MOE DOCK. The docking experiments were performed six times (total 45 000 Â six runs).
Statistical analysis. Statistical analysis was performed using R software. 27 Differences in S scores were evaluated using an unpaired Student's t test. Data represent the mean±standard deviation (s.d.), with Po0.05 regarded as statistically significant.
RESULTS

Enzyme activities
b-Hex A and total b-Hex activities in the patient were 80.1(19% of the mean activity of the controls) and 88.6 nmol per mg protein per hour (10% of the mean activity of the controls), respectively (Table 1) . Based on these lower b-Hex A and total b-Hex activities, the patient was diagnosed as having SD. b-Hex A and total b-Hex activities of the mother were 284.8 (66% of the mean activity of the controls) and 650.3 nmol per mg protein per hour (71% of the mean activity of the controls), respectively (Table 1) .
b-Hex A and total b-Hex activities of the father were 428.8 (100% of the mean activity of the controls) and 1146.2 nmol per mg protein per hour (125% of the mean activity of the controls), respectively ( Table 1) .
The difference in enzyme activity between the patient and her parents suggests that each of the parents possessed a different mutation. Figure 2 Schematic drawing of the steps in the structural formation of the GM2AP/GM2/b-Hex A complex. In this process, we analyzed the conformational stability of the ab-heterodimer (left simulation analysis) and the catalytic ability of b-Hex A (right simulation analysis).
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Genetic analysis
To reveal the relationship between enzyme activity and the mutation, we performed genetic analysis. Direct sequencing of HEXB exons revealed the presence of two mutations in the patient: c.1021delA in exon 8; and c.1514G4A in exon 13 ( Figure 3 ). Genetic analysis of the patient's family members showed that the mother was heterozygous for c.1021delA, and that the father was heterozygous for c.1514G4A.
The c.1021delA mutation may cause a frameshift at amino-acid position 341 and create a translational stop at amino-acid position 371 in the HEXB protein (p.Ser341ValfsX30). The protein is expected to be truncated at B60% of its full length. The nucleotide change of c.1514G4A produces the substitution p.Arg505Gln. To ascertain whether this was not a single-nucleotide polymorphism, we performed direct sequencing of this region in 103 healthy controls, and found that none of them carried this alternative allele. The b-Hex A with p.Arg505Gln was shown to become a heat-labile enzyme, in previous reports. 18, 28, 29 The amino acid at position p.Arg505 is not located in the catalytic site or in the interface between subunits. However, according to Maier et al., 21 p.Arg505 seems important for dimerization of subunits. A short hydrogen bond between p.Arg505 and Arg501 may be associated with dimerization. The substitution p.Arg505Gln may disrupt this hydrogen bond, which would affect the dimerization of subunits.
Western blot analysis
To investigate the mutation effect of p.Ser341ValfsX30 and p.Arg505Gln on expression levels of a-and b-subunit proteins, we performed western blot analysis using total protein in peripheral leukocytes. The control was a healthy volunteer who was confirmed as having no mutations in HEXB. b-Hex A and total b-Hex activities of the control were 510.1 and 1 539.7 nmol per mg protein per hour, respectively. The molecular weights of subunits were detected (as described below) and were consistent with a previous report. 30 The precursor and mature forms of the a-subunits (ap and am) were 67 and 54 kDa, respectively (Figure 4a ). The precursor of b-subunit (bp) was 63 kDa, and the mature forms of the b-subunits (bm) were 52 and 29 kDa (Figure 4c) . To produce the mature form, the precursors of the b-subunits were divided into two peptides through proteolytic processing in the lysosome. The band at 52 kDa corresponds to the complex of two peptides, and that at 29 kDa corresponds to the separated peptide. An anti-b-subunit antibody that we used recognized the N-terminal peptide. The electrophoretic density of each subunit was analyzed using ImageJ (http://rsbweb.nih.gov/ij/), and corrected to its respective density of tubulin. The relative amounts (electrophoretic densities) of the each subunit compared with the control are shown in Figures 4b and d (bar chart) . The amount of bm is shown as the sum of bands in 52 and 29 kDa (Figure 4d) .
The amount of b-subunits of the father having p.Arg505Gln was sufficient, even compared with normal subjects, whereas the amount of b-subunits of the mother having p.Ser341ValfsX30 reduced to less than half the amount of the father or the control (Figure 4d ). From this result, it was inferred that the translated product from the mutant allele of p.Ser341ValfsX30 could not become the b-subunit because of a totally different form and/or degradation in the endoplasmic reticulum. The amount of b-subunits of the patient with p.Ser341ValfsX30 and p.Arg505Gln was reduced further than that of the mother (Figure 4d ). It seems that with the addition of the mutation effect of p.Arg505Gln to the reduction amount of b-subunits, the amount of b-subunits was further decreased. It was observed that, as with the b-subunits, the amounts of mature form of the a-subunits of the patient decreased markedly compared with those of the mother, father and control (Figure 4b ). It is thought that p.Arg505Gln can affect the maturation of a-subunits.
Molecular simulation analysis
To elucidate the pathological significance of p.Arg505Gln, especially the conformational stability of the ab-heterodimer and the catalytic ability of b-Hex A in lysosomes, we performed molecular simulation analysis with the mutant b-subunit. Docking simulation of the a-and b-subunits was carried out using ZDOCK software, which yielded a ZDOCK score that indicated conformational stability. The ZDOCK scores of wild-type b-Hex A (the wild-type a-and b-subunits) and mutant b-Hex A (the wild-type a-subunit and mutant b-subunit) (mean ± s.d.) were 230.07 ± 20.77 and 168.20 ± 11.49, respectively. The ZDOCK scores for mutant b-Hex A were significantly lower than those of wild-type b-Hex A (Po0.001). This indicated that mutant b-Hex A decreased in stability compared with wild-type b-Hex A.
In wild-type b-Hex A, the guanidyl NZH1 of p.Arg505 forms two hydrogen bonds to the backbone oxygen atom or p.Arg501, as described by Maier et al. In our simulation, these hydrogen bonds disappeared in mutant b-Hex A (the wild-type a-subunit and mutant b-subunit) (Figure 5a ). Surface potential analysis using Adaptive Poisson-Boltzmann Solver (APBS) software (http://www.poissonboltzmann.org/apbs/) showed that, in mutant b-Hex A, a slight change in surface potential occurred in the docking sites of the a-and b-subunits (Figure 5b) . Therefore, the change of hydrogen bonds and surface potentials in mutant b-Hex A mentioned above may affect mutant ab-heterodimer formation. Sandhoff disease mutation: p.R505Q in HEXB N Yasui et al
In docking simulations of the GM2AP/GM2 complex and b-Hex A, the 3-D structure of the GM2AP/GM2/b-Hex A complex that resulted was superimposed onto a structure constructed according to the model predicted by Mark et al., 19 and the number of structures with an RMSD of p5 Å were counted. The number of structures with an RMSD of p5 Å per 45 000 runs for wild-type and mutant b-Hex A (mean ± s.d.) were 14.00 ± 8.00 and 9.17 ± 6.85, respectively. The number of mutant b-Hex A was significantly lower than that of wild-type b-Hex A (Po0.01). GM2AP transports GM2 and presents it to the active site of the a-subunit. 2, 19 This result indicated that the GM2AP/GM2 binding abilities of mutant b-Hex A were lower than those of wild-type b-Hex A, and mutant b-Hex A may reduce the chance of proper substrate presentation from GM2AP.
In the docking simulations of GM2 and b-Hex A, the number of structures that met the following conditions was counted: (1) the distance of p5 Å between the oxygen atom in the glycosidic bond of the GM2 terminal b-linked GalNac and the oxygen atom of the carboxylate group in Glu323 of a-subunit; and (2) GM2 oriented so that the C2-acetamido group of the GM2 faced the oxygen atom of the carboxylate group in Asp322 of a-subunit. 19, 20 The numbers of structures with the above conditions per 45 000 runs for wild-type and mutant b-Hex A (mean±s.d.) were 10 708.17±97.17 and 9 565.00 ± 44.43, respectively. The number of mutant b-Hex A was significantly lower than that of wild-type b-Hex A (Po0.001). This indicated that mutant b-Hex A has less favorable orientation of GM2 and reduced GM2 hydrolysis ability.
DISCUSSION
Here, we present the result from our investigation of a Japanese female with adult SD, with a relatively early disease onset. The patient developed symptoms at 6 years of age. At her first clinical examination, when she was 20 years old, she presented ataxia in her trunk and limbs, muscle atrophy, and limb weakness. The age of the patient at disease onset was 10-20 years younger than that of a typical patient Sandhoff disease mutation: p.R505Q in HEXB N Yasui et al with adult SD. However, our patient's symptoms were comparable to those of adult SD, involving only the cerebellum and lower motor neurons. 4, 5, 10 Juvenile SD affects a wider range of nerves. 3 In addition, the slow disease progression in this patient was consistent with adult SD.
In genetic analysis, the patient had compound heterozygous mutations, c.1021delA (p.Ser341ValfsX30) and c.1514G4A (p.Arg505Gln), in HEXB. The mother of the patient had a frameshift mutation, p.Ser341ValfsX30, which created a translational stop, and her enzyme activity reduced by about half. The enzyme activity of the father, who had p.Arg505Gln, was equivalent to that of the controls. To investigate the pathological significance of p.Arg505Gln and the mechanisms leading to disease onset in the patient, we performed western blot analysis and molecular simulation analysis with the mutant b-subunit.
From the results of western blot analysis, the b-subunit was not produced from a mutant allele of p.Ser341ValfsX30. The enzyme activity of b-Hex A was not decreased to the threshold level of that required for developing SD, from the twofold reduction of the bsubunit alone. However, with the additional effects of p.Arg505Gln to p.Ser341ValfsX30, the enzyme activity of b-Hex A was further decreased.
One of the effects of p.Arg505Gln was thought to be a hampering of the maturation of b-Hex A, as western blot analysis showed that the amounts of the mature forms of a-and b-subunits were markedly lower in the patient. p.Arg505Gln may have an influence on the dimerization of ab-subunits from its location, and our docking simulation showed the disappearance of two hydrogen bonds between p.Arg505 and p.Arg501 associated with dimerization and change in surface potential in the docking sites of the mutant b-subunit. Dimerization of the a-and b-subunits was indispensable for the process of maturation of the enzyme. 2, 16, 19 The precursor form of b-Hex A, although not analyzed in this study, has the same binding sites as the a-and b-subunits of the mature form of b-Hex A. If a similar conformational change in the mature form of b-Hex A occurs in the precursor form, the process of maturation of b-Hex A may be hampered not only in lysosomes but also in the endoplasmic reticulum and Golgi bodies. 2, 31 Each subunit can take a maturation process in the form of bb-homodimer and aahomodimer also. 2 The difference in stability of each dimer was reported, in the order of bb4ab44aa. 2 If the stability would change to bb44ab owing to the p.Arg505Gln mutation, although not analyzed in this study, much more mature b-subunits might be derived from the bb-homodimer, and the amount of the mature a-subunit might be decreased, as seen in the result of western blot analysis of the father (Figure 4d ).
Another effect of p.Arg505Gln was thought to be a hindering of the catalytic ability of b-Hex A. Our docking simulation of the a-and b-subunits showed that p.Arg505Gln mutation reduced the conformational stability of mutant b-Hex A, which may alter the binding site of GM2AP/GM2 or GM2. 21 This hypothesis was supported by the significantly lower numbers of properly binding GM2AP/GM2 and GM2 to mutant b-Hex A observed in our docking simulation analysis. Each step in GM2AP/GM2/b-Hex A complex formation was impaired by the mutant b-subunit, which may have resulted in a synergistic negative effect on b-Hex A activity.
Although p.Arg505Gln is predicted to have a negative effect on bHex A activity, SD patients homozygous for p.Arg505Gln show a late disease onset and very mild symptoms according to a report by Delnooz et al., 7 indicating that a p.Arg505Gln mutation has a limited negative effect on b-Hex A activity; the activity of b-Hex A with a mutated b-subunit protein with p.Arg505Gln is maintained to some extent.
Our patient, who carried a p.Arg505Gln mutation and a frameshift mutation in HEXB, showed earlier onset and more severe symptoms than those seen in patients homozygous for p.Arg505Gln. The clinical discrepancy between our patient and patients homozygous for p.Arg505Gln may be due to expression levels of b-subunit protein.
There are two possible treatment strategies for our patient. One is to enhance the expression levels of mutant b-subunit protein with p.Arg505Gln. Transcription-activating drugs, such as histone deacetylase inhibitors, may increase the expression levels of mutant b-subunit protein and ameliorate the severity of the clinical symptoms. The other treatment is chaperone therapy, which increases the conformational stability of b-Hex A. 31 The chemical compounds working as chaperones may also improve residual b-HexA activity.
In conclusion, various methods, including simulation analysis, are useful aids in understanding the effects of the p.Arg505Gln mutation on molecular conformation, and insights into the molecular pathology are helpful in developing novel treatments for lysosomal disorders.
